VIDEO: Optimal sequencing of CD19-targeting therapies in ALL up for debate
In this video, Lori Muffly, MD, MS, discussed a debate session that focused on the sequencing and importance of CD19-targeting therapies from the Society of Hematologic Oncology Annual Meeting.
During the debate, Rebecca Gardner, MD, associate professor in the department of pediatrics in the division of hematology/oncology at Seattle Children’s Hospital, presented on the optimal time to use CAR T-cell therapy and Rachel Rau, MD, assistant professor of pediatrics-oncology at Baylor College of Medicine, presented on the optimal time to use blinatumomab (Blincyto (Amgen).
Muffly noted that although there is no definitive answer when choosing the optimal therapeutic that targets CD19, it is important to consider which treatment best fits certain clinical scenarios.
“Both presenters talked about the use of exploring these therapies more in the upfront or MRD early setting and how the sequencing of therapeutics in ALL is evolving, and we are very fortunate to have these highly effective therapies,” Muffly, associate professor of medicine in the division of blood and marrow transplantation and cellular therapy at Stanford University, said.
Collapse
Gardner R, et al. Acute lymphoblastic leukemia debate. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 8-11, 2021 (virtual meeting).